Trending NewsTrending NewsNASDAQ:UNCY Unicycive Therapeutics (UNCY) Stock Price, News & Analysis $8.26 -0.30 (-3.50%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$8.31 +0.05 (+0.64%) As of 05/15/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Unicycive Therapeutics Stock (NASDAQ:UNCY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Unicycive Therapeutics alerts:Sign Up Key Stats Today's Range$8.12▼$8.5950-Day Range$6.11▼$8.5652-Week Range$3.71▼$11.00Volume828,458 shsAverage Volume571,919 shsMarket Capitalization$220.54 millionP/E RatioN/ADividend YieldN/APrice Target$24.00Consensus RatingModerate Buy Company Overview Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. Read More Unicycive Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreUNCY MarketRank™: Unicycive Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 297th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingUnicycive Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialUnicycive Therapeutics has a consensus price target of $24.00, representing about 190.6% upside from its current price of $8.26.Amount of Analyst CoverageUnicycive Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Unicycive Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Unicycive Therapeutics are expected to grow in the coming year, from ($1.35) to $8.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Unicycive Therapeutics is -3.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Unicycive Therapeutics is -3.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUnicycive Therapeutics has a P/B Ratio of 5.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.02% of the float of Unicycive Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnicycive Therapeutics has a short interest ratio ("days to cover") of 4.62.Change versus previous monthShort interest in Unicycive Therapeutics has recently decreased by 0.48%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUnicycive Therapeutics does not currently pay a dividend.Dividend GrowthUnicycive Therapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.39 News SentimentUnicycive Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Unicycive Therapeutics this week, compared to 6 articles on an average week.Search Interest15 people have searched for UNCY on MarketBeat in the last 30 days. This is an increase of 275% compared to the previous 30 days.MarketBeat Follows3 people have added Unicycive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Unicycive Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.71% of the stock of Unicycive Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.42% of the stock of Unicycive Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Unicycive Therapeutics' insider trading history. Receive UNCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Unicycive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. UNCY Stock News HeadlinesHead-To-Head Analysis: Savara (NASDAQ:SVRA) & Unicycive Therapeutics (NASDAQ:UNCY)May 17 at 4:57 AM | americanbankingnews.comUnicycive Therapeutics Inc Ordinary Shares UNCYMay 16 at 7:56 AM | morningstar.comMALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.May 17 at 1:00 AM | Weiss Ratings (Ad)Unicycive Therapeutics (UNCY) price target decreased by 23.53% to 32.20May 14 at 10:22 PM | msn.comUnicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing?May 14 at 10:22 PM | finance.yahoo.comUnicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | finanznachrichten.deUnicycive Therapeutics Provides Update on FDA Review and Financial Results Ahead of OLC Launch PreparationsMay 12, 2026 | quiverquant.comQUnicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comSee More Headlines UNCY Stock Analysis - Frequently Asked Questions How have UNCY shares performed this year? Unicycive Therapeutics' stock was trading at $5.77 at the beginning of 2026. Since then, UNCY shares have increased by 43.2% and is now trading at $8.26. How were Unicycive Therapeutics' earnings last quarter? Unicycive Therapeutics, Inc. (NASDAQ:UNCY) announced its earnings results on Tuesday, May, 12th. The company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by $0.08. When did Unicycive Therapeutics' stock split? Unicycive Therapeutics's stock reverse split on the morning of Friday, June 20th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 19th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Unicycive Therapeutics IPO? Unicycive Therapeutics (UNCY) raised $25 million in an initial public offering (IPO) on Tuesday, July 13th 2021. The company issued 4,600,000 shares at $5.00-$6.00 per share. Roth Capital Partners acted as the underwriter for the IPO and EF Hutton (formerly Kingswood Capital Markets) was co-manager. Who are Unicycive Therapeutics' major shareholders? Unicycive Therapeutics' top institutional investors include Dimensional Fund Advisors LP (0.54%), OMERS ADMINISTRATION Corp (0.12%) and Renaissance Technologies LLC (0.09%). View institutional ownership trends. How do I buy shares of Unicycive Therapeutics? Shares of UNCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Unicycive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Unicycive Therapeutics investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), ADC Therapeutics (ADCT), Citius Pharmaceuticals (CTXR), DocGo (DCGO), NVIDIA (NVDA) and Adicet Bio (ACET). Company Calendar Last Earnings5/12/2026Today5/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 UNCY's financial health is in the Green zone, according to TradeSmith. UNCY has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:UNCY CIK1766140 Webwww.unicycive.com Phone650-351-4495FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Price Target for Unicycive Therapeutics$24.00 High Price Target$37.00 Low Price Target$15.00 Potential Upside/Downside+190.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($2.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.56 million Net MarginsN/A Pretax MarginN/A Return on Equity-134.69% Return on Assets-84.51% Debt Debt-to-Equity RatioN/A Current Ratio2.40 Quick Ratio2.40 Sales & Book Value Annual Sales$680 thousand Price / Sales324.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book5.86Miscellaneous Outstanding Shares26,700,000Free Float23,840,000Market Cap$220.54 million OptionableNot Optionable Beta1.78 The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:UNCY) was last updated on 5/17/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX Goes Public. Here's What Happens To Your IRA.When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...Americas Gold Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
